NASDAQ:THTX

Theratechnologies Competitors

$3.82
+0.06 (+1.60 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.69
Now: $3.82
$3.84
50-Day Range
$2.87
MA: $3.35
$3.94
52-Week Range
$1.68
Now: $3.82
$3.99
Volume122,200 shs
Average Volume621,987 shs
Market Capitalization$358.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79

Competitors

Theratechnologies (NASDAQ:THTX) Vs. ZYME, ENDP, ZEAL, KROS, TBPH, and ARQT

Should you be buying THTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Theratechnologies, including Zymeworks (ZYME), Endo International (ENDP), Zealand Pharma A/S (ZEAL), Keros Therapeutics (KROS), Theravance Biopharma (TBPH), and Arcutis Biotherapeutics (ARQT).

Theratechnologies (NASDAQ:THTX) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Zymeworks, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02302.60
Zymeworks03712.82

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Zymeworks has a consensus price target of $51.50, indicating a potential upside of 66.13%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Zymeworks.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 75.1% of Zymeworks shares are owned by institutional investors. 4.2% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

Earnings and Valuation

This table compares Theratechnologies and Zymeworks' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$63.22 million5.67$-12,500,000.00($0.14)-27.29
Zymeworks$29.54 million48.45$-145,440,000.00($3.83)-8.09

Theratechnologies has higher revenue and earnings than Zymeworks. Theratechnologies is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Zymeworks' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theratechnologies-37.22%-135.78%-21.36%
Zymeworks-569.13%-44.06%-34.36%

Summary

Zymeworks beats Theratechnologies on 8 of the 15 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Endo International (NASDAQ:ENDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Endo International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02302.60
Endo International23302.13

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Endo International has a consensus price target of $7.6667, indicating a potential upside of 23.66%. Given Theratechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Theratechnologies is more favorable than Endo International.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 80.0% of Endo International shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Endo International has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Earnings and Valuation

This table compares Theratechnologies and Endo International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$63.22 million5.67$-12,500,000.00($0.14)-27.29
Endo International$2.91 billion0.49$-422,640,000.00$2.382.61

Theratechnologies has higher earnings, but lower revenue than Endo International. Theratechnologies is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Endo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theratechnologies-37.22%-135.78%-21.36%
Endo International-5.30%-85.80%7.19%

Summary

Endo International beats Theratechnologies on 8 of the 13 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Zealand Pharma A/S (NASDAQ:ZEAL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Zealand Pharma A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02302.60
Zealand Pharma A/S00203.00

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Zealand Pharma A/S has a consensus price target of $43.00, indicating a potential upside of 31.10%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Zealand Pharma A/S.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 4.3% of Zealand Pharma A/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Earnings and Valuation

This table compares Theratechnologies and Zealand Pharma A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$63.22 million5.67$-12,500,000.00($0.14)-27.29
Zealand Pharma A/S$6.20 million229.60$-85,670,000.00($2.54)-12.91

Theratechnologies has higher revenue and earnings than Zealand Pharma A/S. Theratechnologies is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Zealand Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theratechnologies-37.22%-135.78%-21.36%
Zealand Pharma A/S-214.31%-38.34%-30.40%

Summary

Theratechnologies beats Zealand Pharma A/S on 10 of the 13 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Theratechnologies and Keros Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theratechnologies-37.22%-135.78%-21.36%
Keros TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Keros Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02302.60
Keros Therapeutics00403.00

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Keros Therapeutics has a consensus price target of $78.00, indicating a potential upside of 29.65%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Keros Therapeutics.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 58.4% of Keros Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Theratechnologies and Keros Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$63.22 million5.67$-12,500,000.00($0.14)-27.29
Keros TherapeuticsN/AN/AN/AN/AN/A

Keros Therapeutics has lower revenue, but higher earnings than Theratechnologies.

Summary

Keros Therapeutics beats Theratechnologies on 6 of the 8 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares Theratechnologies and Theravance Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theratechnologies-37.22%-135.78%-21.36%
Theravance Biopharma-345.16%N/A-51.60%

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theratechnologies and Theravance Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02302.60
Theravance Biopharma00703.00

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Theravance Biopharma has a consensus price target of $33.2857, indicating a potential upside of 58.88%. Given Theratechnologies' higher possible upside, equities analysts plainly believe Theratechnologies is more favorable than Theravance Biopharma.

Institutional & Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are owned by institutional investors. 5.9% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Theratechnologies and Theravance Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$63.22 million5.67$-12,500,000.00($0.14)-27.29
Theravance Biopharma$73.41 million18.61$-236,460,000.00($4.25)-4.93

Theratechnologies has higher earnings, but lower revenue than Theravance Biopharma. Theratechnologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Theravance Biopharma beats Theratechnologies on 8 of the 14 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares Theratechnologies and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theratechnologies-37.22%-135.78%-21.36%
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theratechnologies and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02302.60
Arcutis Biotherapeutics00403.00

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Arcutis Biotherapeutics has a consensus price target of $54.6667, indicating a potential upside of 105.36%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Theratechnologies.

Institutional & Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Theratechnologies and Arcutis Biotherapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$63.22 million5.67$-12,500,000.00($0.14)-27.29
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.17

Theratechnologies has higher revenue and earnings than Arcutis Biotherapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Arcutis Biotherapeutics beats Theratechnologies on 7 of the 11 factors compared between the two stocks.


Theratechnologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zymeworks logo
ZYME
Zymeworks
1.8$31.00+1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20+1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80+1.5%$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16+4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95+3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62+3.5%$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84+0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80+3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35+2.6%$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51+1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90+7.8%$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69+2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49+0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70+1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39+2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23+3.0%$1.18 billionN/A0.00Lockup Expiration
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58+0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38+8.0%$1.15 billionN/A-8.88News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07+1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54+1.6%$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78+0.7%$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23+2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81+1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50+1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27+0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42+7.3%$1.07 billion$120,000.00-3.86News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57+1.3%$1.07 billionN/A-8.82
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16+2.8%$1.07 billion$1.52 million-11.79News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27+1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28+1.6%$1.06 billionN/A0.00
MannKind logo
MNKD
MannKind
1.4$4.24+1.9%$1.05 billion$63.04 million-20.19News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54+0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75+1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00+1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76+1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37+0.2%$958.34 millionN/A-26.27
Annexon logo
ANNX
Annexon
1.9$24.93+0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25+1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49+2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78+3.1%$911.34 million$810,000.00-8.90Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25+2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87+0.4%$881.43 millionN/A-10.64Analyst Report
Gap Down
Merus logo
MRUS
Merus
1.6$23.06+1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75+0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74+19.0%$860.30 million$23.96 million-16.51Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37+0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89+0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33+1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57+7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37+1.1%$775.18 million$322.07 million-5.11
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.